Marketing Clinical Research
(Natural Products Insider, 18.06.15)
Clinical trials are a vital part of the marketing messages supplement companies use to connect with and educate consumers, but regulations and study design are factors to be considered before marketing or research begins. As marketing goals increasingly demand the use of health benefit claims and regulatory agencies increasingly take action against violative claims, it is important for marketing goals and personnel to be involved in the process of clinical study design.
Is Legacy Healthcare Marketing Obstructing Healthcare Consumerism?
It’s well documented that the healthcare consumer and patient is actively engaged in searching for quality and price information when selecting healthcare providers. Social media, web sites, mobile apps and other channels play significant roles in the consumer informational quest. Each day more and more disruptive innovation takes place that brings the data healthcare consumers need to the forefront in spite of hospitals and health systems. News coverage by electronic and print channels is also intensifying the pressure for price and quality transparency.
5 Ways Providers Can Improve Marketing in the Mobile Age
(Health Data Management, 10.06.15)
The age of consumer empowerment has arrived in the healthcare industry. Medical patients are now acting like informed customers. They’re using digital and mobile technology to research doctors and become more informed of healthcare choices. They expect providers to make it easy to learn about their credentials, read patient reviews, and book appointments online.
Biosimilar Uptake Will Require Companies to Tell a Trustworthy Backstory
(Medical Marketing & Media, 12.03.15)
Novartis still has to win a patent-infringement lawsuit before it can sell Zarxio, the first biosimilar to receive FDA approval, but experts and advocates indicate the potential rollout of the drug is less important than the fact that the approval has smoothed the way for the four biosimilar applications in front of the FDA.
“Details create the big picture.” —Sanford I. Weill